Clinical Trial Update: Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 safety study of carfilzomib (PR-171) in hematologic malignancies has completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Carfilzomib (carfilzomib)

Snippet

Sponsor: Amgen | Conditions: Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2015-12-03